Abbvie stock forecast 2025 estimates revenue resilience amid U

AbbVie stock forecast 2025 estimates revenue resilience amid U.S. biosimilar pressures. Analysts project newer product sales potentially exceeding $15 billion, enough to sustain overall net profit margins near 20%. Private investors in the Simply Wall St Community estimate AbbVie’s fair value between US$187.76 and US$437.76, reflecting broad disagreement across eight viewpoints. With strong immunology sales acting as a catalyst, consider how concentrated product exposure shapes both optimism and caution among market participants. US FDA slaps new requirements for Indonesia's shrimp and spices after radioactive contamination Current projections for AbbVie stock forecast 2025 suggest mid-to-high single-digit revenue growth, supported by strategic diversification into oncology and neuroscience. Valuation models from major investment banks peg forward P/E ratios around 14–15, which may position ABBV attractively compared to healthcare sector peers.